Platinum exposure and cause‐specific mortality among patients with testicular cancer

BACKGROUND: Although testicular cancer (TC) treatment has been associated with severe late morbidities, including second malignant neoplasms (SMNs) and ischemic heart disease (IHD), cause‐specific excess mortality has been rarely studied among patients treated in the platinum era. METHODS: In a larg...

Descripción completa

Detalles Bibliográficos
Autores principales: Groot, Harmke J., van Leeuwen, Flora E., Lubberts, Sjoukje, Horenblas, Simon, de Wit, Ronald, Witjes, J. Alfred, Groenewegen, Gerard, Poortmans, Philip M., Hulshof, Maarten C. C. M., Meijer, Otto W. M., de Jong, Igle J., van den Berg, Hetty A., Smilde, Tineke J., Vanneste, Ben G. L., Aarts, Maureen J. B., Jóźwiak, Katarzyna, van den Belt‐Dusebout, Alexandra W., Gietema, Jourik A., Schaapveld, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004069/
https://www.ncbi.nlm.nih.gov/pubmed/31730712
http://dx.doi.org/10.1002/cncr.32538
Descripción
Sumario:BACKGROUND: Although testicular cancer (TC) treatment has been associated with severe late morbidities, including second malignant neoplasms (SMNs) and ischemic heart disease (IHD), cause‐specific excess mortality has been rarely studied among patients treated in the platinum era. METHODS: In a large, multicenter cohort including 6042 patients with TC treated between 1976 and 2006, cause‐specific mortality was compared with general population mortality rates. Associations with treatment were assessed with proportional hazards analysis. RESULTS: With a median follow‐up of 17.6 years, 800 patients died; 40.3% of these patients died because of TC. The cumulative mortality was 9.6% (95% confidence interval [CI], 8.5%‐10.7%) 25 years after TC treatment. In comparison with general population mortality rates, patients with nonseminoma experienced 2.0 to 11.6 times elevated mortality from lung, stomach, pancreatic, rectal, and kidney cancers, soft‐tissue sarcomas, and leukemia; 1.9‐fold increased mortality (95% CI, 1.3‐2.8) from IHD; and 3.9‐fold increased mortality (95% CI, 1.5‐8.4) from pneumonia. Seminoma patients experienced 2.5 to 4.6 times increased mortality from stomach, pancreatic, bladder cancer and leukemia. Radiotherapy and chemotherapy were associated with 2.1 (95% CI, 1.8‐2.5) and 2.5 times higher SMN mortality (95% CI, 2.0‐3.1), respectively, in comparison with the general population. In a multivariable analysis, patients treated with platinum‐containing chemotherapy had a 2.5‐fold increased hazard ratio (HR; 95% CI, 1.8‐3.5) for SMN mortality in comparison with patients without platinum‐containing chemotherapy. The HR for SMN mortality increased 0.29 (95% CI, 0.19‐0.39) per 100 mg/m(2) platinum dose administered (P (trend) < .001). IHD mortality was increased 2.1‐fold (95% CI, 1.5‐4.2) after platinum‐containing chemotherapy in comparison with patients without platinum exposure. CONCLUSIONS: Platinum‐containing chemotherapy is associated with a dose‐dependent increase in the risk of SMN mortality.

Ejemplares similares